#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Diabetes insipidus Pouchitis Pancreatic carcinoma metastatic Pulmonary fibrosis Autoinflammation with infantile enterocolitis Cluster headache Immunodeficiency common variable Anaemia Thrombotic thrombocytopenic purpura Oropharyngeal squamous cell carcinoma Cutaneous T-cell lymphoma Sjogren's syndrome Piriformis syndrome Leukoencephalopathy Congenital hypotransferrinaemia More trials…

    Learn about Rare Diseases

    Proteus syndrome Glycogen storage disease type II – Trials in Disease Testicular leiomyosarcoma – Trials in Disease Andersen-Tawil syndrome – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Glycogen storage disease type V Small intestine leiomyosarcoma – Diagnostics Idiopathic pulmonary fibrosis – Basic Information Undifferentiated sarcoma – Trials in Disease Haemophilia B with anti factor IX – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Botulinum Toxin Type A Hydroxyzine Hydrochloride Azathioprine Suvecaltamide Metoprolol Ambrosia Artemisiifolia (302) Doxecitine IHMA-2121771-1 MRNA-1345 Fingolimod Sufentanil IMMUNOSTEM Adagrasib Clofutriben Fluticasone Propionate Anhydrous Cyclophosphamide Nebivolol Acenocoumarol Mps-200 Amiodarone Hydrochloride More therapies…

    Learn about Your Condition

    Gout Laryngeal cancer stage III Urinary incontinence Vulvovaginal pruritus Pneumothorax Malignant neoplasm of choroid Oesophageal disorder Benign neoplasm of ureter Head and neck cancer stage IV Myositis Anogenital warts Post procedural infection Thrombectomy Colitis ulcerative Henoch-Schonlein purpura More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Med Polonia Sp. z o.o.

Med Polonia Sp. z o.o.

Obornicka 262, Poznan, 60-693, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of aneratrigine mesilate (iN1011-N17-02) to find the best dose for treating pain in adults with post-herpetic neuralgia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • ANERATRIGINE MESILATE
    • Tramadol Hydrochloride
    • Paracetamol
    Bulgaria Poland

  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections

    Not recruiting

    2 1
    Investigated Drugs:
    • Sibeprenlimab
    Bulgaria Germany Greece Poland Romania Spain

  • Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sonelokimab
    • Risankizumab
    Bulgaria Czechia France Germany Hungary Poland +1

  • Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Fenebrutinib
    • Teriflunomide
    Finland Germany Hungary Italy Poland Portugal +1

  • Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Docetaxel
    Belgium France Germany Italy The Netherlands Poland +1

  • Safety Study of GEN1046 and Pembrolizumab in Patients with Malignant Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Acasunlimab
    • Carboplatin
    • Cisplatin
    Hungary Italy Poland Spain

  • Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Bemcentinib
    • Carboplatin
    • Pembrolizumab
    France Greece Hungary Italy Poland Spain

  • Study Comparing Ivonescimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Squamous Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Carboplatin
    • Paclitaxel
    Belgium France Germany Greece Ireland Italy +3

  • Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Bulgaria Denmark France Germany Greece +5
Previous Page
1 … 3 4 5 6 7 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!